 "Lupin managing director Nilesh Gupta")
Drug maker Lupin posted flat revenue growth and lower profit in the fourth quarter as the business came under pressure in the US market. Lupin managing director Nilesh Gupta tells Aneesh Phadnis that the company will face challenges in FY18 but will clock growth in the following year on the back of new launches. Excerpts:
Lupin's fourth quarter revenue growth over a year ago was flat and the same declined sequentially. What went wrong?
We had indicated earlier that sales will be muted. We have seen competition in Glumetza, which is among our top-selling diabetes drugs. We continue to see meaningful
